Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,061

Document Document Title
WO/2022/168861A1
The present invention provides a polypeptide having an amino acid sequence capable of binding to NRP1 and an amino acid sequence capable of inducing apoptosis.  
WO/2022/166977A1
Provided are an anti-human IL-36R monoclonal antibody and an application thereof. A murine anti-human IL-36R monoclonal antibody is prepared by a hybridoma technology; the murine anti-human IL-36R antibody is screened to obtain an antibo...  
WO/2022/166720A1
Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fus...  
WO/2022/170179A1
The present invention features methods and compositions directed towards a recombinant polypeptide biopolymer composition that are effective as nano springs. The composition of the present invention comprises both a streptavidin polypept...  
WO/2022/165608A1
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the su...  
WO/2022/166365A1
Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellul...  
WO/2022/166806A1
Provided is a novel CD271-based antigenic epitope peptide. The epitope peptide is: (1) located in SEQ ID NO.1; or (2) located in an amino acid sequence having at least 80% identity with the sequence SEQ ID NO.1 in (1), SEQ ID NO.1 contai...  
WO/2022/166895A1
Provided are a novel Cas effector protein that can exhibit a nuclease activity in cells and outside of cells and the use thereof.  
WO/2022/166831A1
The present invention relates to a recombinant fusion protein and a nano-assembly, and preparation methods therefor and the use thereof. The nano-assembly is formed by means of combining at least one recombinant fusion protein and a hydr...  
WO/2022/166665A1
The present application provides an endogenous chimeric antigen receptor (ECAR). An antigen-binding domain in the endogenous chimeric antigen receptor is an endogenous protein molecule. The engineered immune cells in the present inventio...  
WO/2022/164222A2
Provided is a pharmaceutical composition for prevention or treatment of pulmonary diseases, the pharmaceutical composition comprising a GIP derivative, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conju...  
WO/2022/161472A1
The present disclosure provides single domain antibodies that bind to SARS-CoV-2 S1, and fusion proteins comprising same. Pharmaceutical compositions, kits and methods of preventing or treating a disease or disorder such as a respiratory...  
WO/2022/162623A1
The present disclosure relates to systems, compositions and methods for modifying target nucleic acid sequences.  
WO/2022/161409A1
The present invention provides a bispecific CS1-BCMA CAR-T cell and an application thereof. Specifically, the present invention provides a bispecific CAR, which comprises CS1 scFv and BCMA scFv, and a 4-1BB co-stimulatory domain and a CD...  
WO/2022/162533A1
The present invention relates, in general, to polypeptides capable of neutralizing SARS-CoV-2 and providing ACE2 enzymatic activity, and uses of these polypeptides for treating disorders related coronaviral infections (COVID-19) and the ...  
WO/2022/160601A1
Disclosed are a gallium 68 labeled affibody protein PET imaging agent and a use; the imaging agent comprises 68Ga-Z-tri; the 68Ga-Z-tri is obtained by labeling an affibody protein with gallium 68; the affibody protein comprises a PDGFR-...  
WO/2022/163647A1
Provided is a vaccine that can be administered orally against coronavirus infection. A vaccine that can be administered orally against coronavirus infection can be provided by transformed bifidobacteria designed so as to present some or ...  
WO/2022/160057A1
In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In asp...  
WO/2022/162704A1
The present invention discloses a therapeutic composition comprising fusion protein with reduced heterogeneity in the glycosylation profile of the protein and methods thereof. More particularly the invention provides the composition with...  
WO/2022/162191A2
This invention describes the formation and use of collections of pMHC Multiplexers. A pMHC Multiplexer is a spatially confined composition of at least two molecules, an encoding molecule and a peptide (and/or protein) that is encoded by ...  
WO/2022/156189A1
The use of a polypeptide compound in the preparation of a drug for the prevention or treatment of inflammatory bowel disease and intestinal fibrosis related thereto. The polypeptide compound contains a parent peptide as represented by th...  
WO/2022/159741A1
The present invention relates to nucleases or nucleic acids encoding the nucleases, RNA guides or nucleic acids encoding the RNA guides, processes for characterizing the nucleases and/or RNA guides, compositions comprising the nucleases ...  
WO/2022/157714A1
The present disclosure relates to a single domain antibody that specifically binds to the epitope in the catalytic domain of carbonic anhydrase IX (CA-IX). The single domain antibody has a dissociation constant (KD) of 1 x 10-7 or lower ...  
WO/2022/159620A1
Provided herein are methods and compositions relating to adenosine A2A receptor libraries having nucleic acids encoding for a scaffold comprising an adenosine A2A binding domain. adenosine A2A receptor libraries described herein encode f...  
WO/2022/156531A1
Disclosed are a dynein binding peptide capable of permeating through a biological barrier, and the use thereof. The polypeptide provided by the present invention is a polypeptide A or a polypeptide B, wherein the polypeptide A is sequent...  
WO/2022/159730A1
A method of treating lung inflammation caused by a viral infection is disclosed. The method of treatment can include topoisomerase I inhibitors and pharmaceutical compositions comprising topoisomerase I inhibitors, which can be administe...  
WO/2022/156786A1
Provided is a chimeric antigen receptor-engineered NK cell, the chimeric antigen receptor comprising: an extracellular target molecule binding domain, a transmembrane region domain, and an intracellular signal transduction domain. The tr...  
WO/2022/158505A1
This material for virus concentration comprises: a fiber aggregate that has fibers; and an antibody that is against a target virus and is supported on the surface of the fibers. The median fiber diameter of the fibers is less than 20 μm...  
WO/2022/155706A1
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one a...  
WO/2022/159433A1
This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering one or more polypeptides of the invention to a subject in need thereof. The viral infect...  
WO/2022/159395A1
Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2022/153307A1
Type I membrane proteins heterodimers are provided. Accordingly, there is provided a heterodimer comprising two polypeptides selected from the group consisting of SIRP alpha, PD1, TIGIT, LILRB2 and SIGLEC10, wherein each of the two polyp...  
WO/2022/154632A1
Disclosed is a switching peptide that can be applied to an electrochemical immunoassay. The switching peptide includes: a peptide compound capable of binding reversibly to a binding antibody; and a chemical marker grafted to the peptide ...  
WO/2022/150899A1
The present invention relates to the field of diagnostic medicine, vaccinology and biotechnology. More specifically, the present invention relates to a chimeric protein for use in diagnosing visceral leishmaniasis in humans and dogs, inc...  
WO/2022/152186A1
Provided is a fully human single-domain tandem chimeric antigen receptor (CAR) capable of specifically binding to a CD5 protein, which CAR contains a CD5 binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellul...  
WO/2022/151958A1
Provided are a human CD276-targeting monoclonal antibody and an application thereof. Specifically, provided are a CD276-targeting antibody, which has a high affinity and a high specificity for human CD276. Further provided are a pharmace...  
WO/2022/154127A1
The present invention provides a desired antibody or antibody composition by modifying a thiol group chemically introduced into an antibody. More specifically, the present invention provides an antibody composition, etc., having desired ...  
WO/2022/152308A1
Provided herein is an engineered dimeric antibody comprising in each monomer a Fab domain specifically binding to a Trop2 antigen operably linked to an engineered hinge region, wherein the engineered hinge region is composed of a portion...  
WO/2022/155503A1
Provided herein are multispecific antigen binding proteins that selectively bind a particular KKLC-1 (CT-83) shared antigen and CD3, as well as related methods, kits, and compositions. Included herein are multispecific antigen binding pr...  
WO/2022/151959A1
The present invention provides a CAR-T cell targeting B7-H3 and an application thereof in the treatment of acute myeloid leukemia (AML). Specifically, the present invention provides a CAR-T cell targeting B7-H3, which comprises an scFv w...  
WO/2022/153698A1
The purpose of the present invention is to provide a chimeric target factor receptor which can activate an antigen presenting cell, e.g., a dendritic cell, in a target-factor-specific manner. A chimeric target factor receptor is provided...  
WO/2022/151746A1
A fusion enzyme and the use thereof in a paper-based biosensor. A GDH-linker-CBM fusion enzyme constructed by a flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase (GDH) gene and a carbohydrate binding module (CBM) gene, wh...  
WO/2022/154547A1
Disclosed is a switching peptide applicable to a multiplex immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a mass label substance bound to the peptide compo...  
WO/2022/150878A1
Peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor, a luteinizing hormone receptor, or an Anti-Mullerian hormone receptor) are described herein. In addition, nanoparticle const...  
WO/2022/155258A1
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and...  
WO/2022/154548A1
Disclosed is a switching peptide that can be applied to an optical one-step immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a fluorescent marker bound to th...  
WO/2022/149934A1
The present invention relates to an antibody-polyethylene glycol-photosensitizer conjugate for anticancer immunotherapy of cancer cells in which a specific receptor is overexpressed. The conjugate improves the cancer cell targeting abili...  
WO/2022/148255A1
Provided is a chimeric antigen receptor (CAR) for activating dendritic cells (DCs) in an immunosuppressive tumor environment. Compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising polynucleotides encoding ...  
WO/2022/149609A1
The present invention addresses the problem of establishing a means for providing a component vaccine that can achieve both of the induction of cellular immunity mainly associated with MHC class I and the induction of humoral immunity as...  
WO/2022/148491A1
Disclosed are a method and application for testing the concept of biological substances such as proteins, peptides, viruses, and microorganisms or biological small molecular substances by linking a single-domain antibody or a scFv or Fab...  

Matches 1 - 50 out of 20,061